Clinical Trial Update: A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two doses of Aramchol versus placebo in non-alcoholic steatohepatitis (NASH) completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatty Liver
• Liver Diseases
• Liver Fibrosis
• Non-alcoholic Steatohepatitis

Drugs mentioned

• Aramchol

Snippet

Sponsor: Galmed Research and Development, Ltd. | Conditions: Fatty Liver, Non-Alcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2021-07-14